Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARRIS - Another partner -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (310)	12/9/1997 5:04:00 PM
From: chirodoc	Read Replies (1) \| Respond to of 353

<<<<<The other possibility is that the selling pressure from the fund's reduction in holdings ceased, and people thought (as I do) that Arris looks cheap, with or without SQNA. ......are you buying arrs or will you wait to see what plays out?

To: Biomaven who wrote (310)	12/9/1997 9:51:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 353

Thanks Peter. Agree that ARRS was/is cheap at current level with or without SQNA. But I can agree with TBF and others who thing that SQNA merge (with 10-15 % premium) are reasons for ARRS price decline (from 13.5 to 9.5 or ~40% decline). How should SQNA SH felt about this opposition to merge news? ARRS needs more SQNA than opposite and small premium (not 35%) is normal in this situation. What is the % of SQNA price devaluation in current ARRS price? I can't hide that I do like Delta technology (in theory), but how about real world, in vivo? Recent BMY deal is confirmation of the approach, but as James stated, how strong confirmation ??? Anyway, If I will have to decide between SQNA and ARRS (own both) I will chose SQNA. mz